CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −450 | $69.09 | $31K | 575,686 |
| 2026-05-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −11,217 | $67.49 | $757K | 4,387,230 |
| 2026-05-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −8,334 | $68.38 | $570K | 4,378,896 |
| 2026-05-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −449 | $69.09 | $31K | 4,378,447 |
| 2026-04-30 | Apuli Maricel Chief Accounting Officer | Sale 10b5-1 | −2,000 | $71.58 | $143K | 134,115 |
| 2026-04-10 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −20,000 | $74.60 | $1.5M | 595,686 |
| 2026-04-10 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −20,000 | $74.60 | $1.5M | 4,398,447 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,200 | $73.64 | $530K | 628,486 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −5,300 | $74.60 | $395K | 623,186 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,500 | $75.55 | $567K | 615,686 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,072 | $73.64 | $521K | 4,431,375 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −5,128 | $74.57 | $382K | 4,426,247 |
| 2026-04-09 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −7,800 | $75.53 | $589K | 4,418,447 |
| 2026-03-18 | Trimarchi Thomas President and CFO | Grant or award | +59,041 | 395,626 | ||
| 2026-03-18 | Apuli Maricel Chief Accounting Officer | Grant or award | +14,170 | 136,115 | ||
| 2026-03-17 | Kumar Neil Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +40,570 | 40,570 | ||
| 2026-03-17 | Kumar Neil Chief Executive Officer | Grant or award · Restricted Stock Units | +104,313 | 104,313 | ||
| 2026-03-13 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −9,690 | $68.36 | $662K | 645,996 |
| 2026-03-13 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −10,310 | $69.20 | $713K | 635,686 |
| 2026-03-13 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −10,241 | $68.39 | $700K | 4,448,206 |
Page 7 of 19 · 373 trades